Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG) (Journal article)

Kosmidis, P. A./ Fountzilas, G./ Eleftheraki, A. G./ Kalofonos, H. P./ Pentheroudakis, G./ Skarlos, D./ Dimopoulos, M. A./ Bafaloukos, D./ Pectasides, D./ Samantas, E./ Boukovinas, J./ Lambaki, S./ Katirtzoglou, N./ Bakogiannis, C./ Syrigos, K. N.


BACKGROUND: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer. PATIENTS AND METHODS: Chemotherapy-naive patients, stage IIIbwet and IV with performance status (0-1), were randomized to receive paclitaxel 200 mg/m(2) on day 1 plus gemcitabine 1 gm/m(2) (group A) on days 1 and 8 every 3 weeks or paclitaxel 80 mg/m(2) plus vinorelbine 22.5 mg/m(2) (group B) on days 1, 8 and 15 every 4 weeks. RESULTS: A total of 398 out of 415 patients were eligible for analysis on intent-to-treat basis (group A: 196, group B: 202). Progression-free survival (PFS) was 5.0 months [95% confidence interval (CI) 4.3-5.6] and 4.4 months (95% CI 3.7-5.2) for groups A and B respectively (P=0.365). Median survival was 11.1 months (95% CI 9.2-13.0) and 8.6 months (95% CI 7.0-10.2) for groups A and B respectively (P = 0.147). Grade 3/4 neutropenia and leukopenia were worse in group B (P<0.001, in both cases). Febrile neutropenia and severe infections were more prominent (P<0.001, P=0.029 respectively) in group B. CONCLUSION: Although response rate, PFS and survival were non-different in both groups, toxicity was significantly worse in group B and therefore further investigation of P-Vin is of no value.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Aged, 80 and over,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use,Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology,Deoxycytidine/administration & dosage/adverse effects/*analogs &,derivatives/therapeutic use,Disease-Free Survival,Drug Administration Schedule,Female,Greece,Humans,Lung Neoplasms/*drug therapy/pathology,Male,Middle Aged,Paclitaxel/administration & dosage/adverse effects/*therapeutic use,Vinblastine/administration & dosage/adverse effects/*analogs &,derivatives/therapeutic use
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/19491
ISSN: 1569-8041
Link: http://www.ncbi.nlm.nih.gov/pubmed/20880999
http://annonc.oxfordjournals.org/content/22/4/827.full.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Kosmidis-2011-Paclitaxel and gemci.pdf409.98 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/19491
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.